Hikma completes acquisition of Teligent sterile injectable assets

Press Release

Hikma completes acquisition of Teligent sterile injectable assets

London, 3 February 2022 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that, following its announcement on 17 January that it had agreed to acquire the Canadian assets of Teligent Inc. for $45.75 million, this transaction has now completed.

The acquisition marks Hikma’s expansion into Canada and includes a portfolio of 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approved by Health Canada.

Riad Mishlawi, President of Hikma Injectables, commented, “The completion of this acquisition expands Hikma’s presence in the highly attractive Canadian injectables market, bringing a strong portfolio of sterile injectable products, as well as strengthening our pipeline.  We are excited to bring these important products to our Canadian customers and their patients.”